The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. Keeping that in mind, here are three stocks where Wall Street’s enthusiasm may be misplaced and some other investments worth exploring instead.
Camping World (CWH)
Consensus Price Target: $10.56 (90.2% implied return)
Founded in 1966 as a single recreational vehicle (RV) dealership, Camping World (NYSE: CWH) still sells RVs along with boats and general merchandise for outdoor activities.
Why Should You Sell CWH?
- Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new locations
- Performance over the past three years was negatively impacted by new share issuances as its earnings per share dropped by 67.5% annually, worse than its revenue
- High net-debt-to-EBITDA ratio of 8× could force the company to raise capital on unfavorable terms if market conditions deteriorate
At $5.55 per share, Camping World trades at 8.3x forward P/E. Read our free research report to see why you should think twice about including CWH in your portfolio.
Yum China (YUMC)
Consensus Price Target: $61.92 (49.2% implied return)
One of China’s largest restaurant companies, Yum China (NYSE: YUMC) is an independent entity spun off from Yum! Brands in 2016.
Why Do We Think Twice About YUMC?
- Annual sales growth of 5.5% over the last seven years lagged behind its restaurant peers as its large revenue base made it difficult to generate incremental demand
- Poor same-store sales performance over the past two years indicates it’s having trouble bringing new diners into its restaurants
- Lacking pricing power results in an inferior gross margin of 20.3% that must be offset by turning more tables
Yum China is trading at $41.49 per share, or 12.8x forward P/E. Dive into our free research report to see why there are better opportunities than YUMC.
Corcept (CORT)
Consensus Price Target: $141 (22% implied return)
Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ: CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.
Why Does CORT Worry Us?
- Earnings per share fell by 16.1% annually over the last five years while its revenue grew, showing its incremental sales were much less profitable
- Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 25.7 percentage points
- Diminishing returns on capital suggest its earlier profit pools are drying up
Corcept’s stock price of $115.57 implies a valuation ratio of 24.7x forward P/E. Check out our free in-depth research report to learn more about why CORT doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
